Hey Fireman, for what it's worth I think they have indeed found a link between blood concentration and dose related response...so as a scientist myself the next step would be to work out what is effecting the blood concentration levels which would either be an uptake problem from gut in some individuals or and enzymatic breakdown happening faster in some people...so the two logical places to look would be the liver and gut first...with the gut you would be looking at bacteria, translocation mechanisms... In liver, is there a pathway of consumption/degradation....a good example of this would be the difference in alcohol consumption....some people can drink like a fish because of alcohol dehydrogenase enzymes being abundant and others lack them or have smaller numbers so the blood levels of alcohol stay higher for longer...so what I have taken out of the extrapolated info. Is A2-73 is a game changer but we need to figure out how to preserve integrity of the molecule while stabilizing the relationship between dosage and effect per unit of dosage change...so to achieve this, it may be a symbiotic bacteria that is lacking in some people, an enzyme lacking in gut or to much of a particular metabolic enzyme in some people...this can then be solved in a few ways in my opinion...those which can respond like our super responders then just take oral...the others may have to take a modified version which either allows for uptake or prevents/slows down metabolic breakdown/half life, or may have to introduce a specific bacteria to gut to aid uptake or maybe take a suppository...I say suppository because in the rectum the arteries go straight in to circulation...I.e. Bypass the liver were by helping to minimize first wave effect of liver metabolism...eitherway we have at minimum the building blocks for major quality of life change in the CNS space in A2-73...if this wasn't the case you would see many other respected scientists saying much the same as they are saying about the plaque-amyloid/tau theories and how they aren't going anywhere...and you would have the BP's full court pressing negative press, etc...It's my belief we are moving slower than a typical large company trail because we have a small cash reserve to make sure it's all done right, there is a big ideological change happening in FDA which effects us with guidances directly, and as a small fish in a big pond we are hiding in the weeds from the big fish until the timing is right for acquisition or going it alone...hard to think but there isn't a big gap between big Pharm and government so we got to play the game wisely or lose because of some policy change designed to stop the train of hope...unfortunately greed is real and not all politicians really care about their constituents as much as we would like to think it's not the case....stay the course longs, we have a real drug here I believe and we are getting 100% value for half the price...
